Related Experiment Videos
Hepatitis B infection in patients with lymphomas
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam.
Hematological Oncology
|September 1, 1990
Summary
Lymphoma patients show a high prevalence of hepatitis B surface antigen, leading to increased hepatic complications during treatment. However, hepatitis B infection does not appear to cause or promote lymphoma development.
Area of Science:
- Hepatology
- Oncology
- Virology
Background:
- Hepatitis B infection is a global health concern.
- Lymphoma is a type of cancer that affects the lymphatic system.
- The interplay between hepatitis B and lymphoma is not fully understood.
Purpose of the Study:
- To investigate the clinical characteristics and treatment outcomes of lymphoma patients with known hepatitis B status.
- To compare outcomes between hepatitis B surface antigen positive and negative patients.
- To analyze the impact of lymphoma treatment on hepatitis B positive patients.
Main Methods:
- Retrospective review of 484 Chinese lymphoma patients.
- Determination of hepatitis B status at diagnosis.
- Analysis of hepatic complications during lymphoma therapy.
Main Results:
- Lymphoma patients had a 22% hepatitis B surface antigen positive rate, significantly higher than controls.
- Hepatitis B surface antigen positive patients were younger but had similar treatment outcomes.
- Hepatic complications occurred in 21% of hepatitis B surface antigen positive patients, including fatal liver failure.
Conclusions:
- Hepatitis B infection contributes to hepatic complications during lymphoma therapy.
- Lymphoma itself may lead to a higher prevalence of hepatitis B surface antigen.
- Further research is needed to explore prevention strategies for hepatic complications.